Brookstone Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History
Bought
Maintained
Sold
Other funds holding BDTX
Brookstone Capital Management's BDTX Position: Q3 2026 in Review
Brookstone Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q3 2026, closing a stake of 13,484 shares — an estimated $24.9K sold.
Brookstone Capital Management first reported a position in BDTX in Q1 2026 and held it in 2 quarters. The position peaked at $30.4K in Q1 2026. 111 funds tracked by Wall St. Rank hold BDTX as of Q3 2026.
- Brookstone Capital Management reported no remaining Black Diamond Therapeutics position as of Q3 2026 after selling out during the quarter.
- Brookstone Capital Management sold 13,484 Black Diamond Therapeutics shares in Q3 2026, an estimated $24.9K.
- Brookstone Capital Management first reported a position in Black Diamond Therapeutics in Q1 2026 and held it in 2 quarters.
- Brookstone Capital Management's Black Diamond Therapeutics position peaked at $30.4K in Q1 2026.
- 111 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2026.
Based on Brookstone Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.